Why Was Elavil Discontinued and Is It Still Prescribed?

Elavil, the original brand name for the tricyclic antidepressant amitriptyline, was discontinued by its manufacturer for commercial reasons, not because regulators deemed the drug unsafe or ineffective. The active ingredient, amitriptyline, never left the market. It remains available as a generic and is prescribed millions of times a year across a range of conditions that go well beyond depression. The story behind Elavil’s disappearance is less about a dangerous drug being pulled and more about a decades-old brand losing its commercial footing once generic competition and newer antidepressants arrived.

How Elavil Rose and Fell as a Brand

Amitriptyline was the second tricyclic antidepressant to reach the market, launched under the brand name Elavil in 1961 for major depressive disorder.¹ For roughly three decades it was among the most widely prescribed antidepressants in the world. Its patent protection eventually expired, and generic amitriptyline became available at a fraction of the brand-name cost. Around the same time, selective serotonin reuptake inhibitors (SSRIs) like fluoxetine (Prozac) arrived in the late 1980s and were marketed heavily as safer, easier-to-use alternatives. Prescribers shifted away from tricyclics for routine depression treatment, and the commercial rationale for maintaining the Elavil brand eroded. The manufacturer stopped producing Elavil, but the FDA never revoked approval for amitriptyline itself. Any pharmacy can dispense the generic, and many do.

This distinction trips people up. When you search for Elavil and find it listed as “discontinued,” that refers to the branded product, not the molecule. It is the pharmaceutical equivalent of a store-brand cereal outlasting the name brand that came first. If your doctor writes a prescription for amitriptyline today, it will be filled without issue.

Why Doctors Moved Away from It for Depression

Amitriptyline is effective for depression. A large network meta-analysis covering more than 100,000 patients across 432 randomized trials found that amitriptyline was the single most effective antidepressant out of 21 drugs studied in head-to-head comparisons.² A separate meta-analysis focused on hospitalized patients with depression found that among individual tricyclics, only amitriptyline was significantly more effective than the SSRIs it was compared against.³

The problem was never efficacy. It was tolerability. That same Lancet analysis found amitriptyline was among the antidepressants with the highest dropout rates, meaning patients were more likely to stop taking it because of side effects.² SSRIs were not necessarily better at treating depression, but patients tolerated them more easily, and they were far less dangerous in overdose. For a condition where the patient population includes people at risk of self-harm, a drug that can cause fatal cardiac complications if someone takes too many pills is a serious liability. Those factors, combined with aggressive pharmaceutical marketing of SSRIs, meant amitriptyline lost its default position in depression treatment over the course of the 1990s.

The Side-Effect Profile That Shaped Its Reputation

Amitriptyline blocks a number of receptors beyond the ones involved in mood. Its anticholinergic activity is the main culprit behind the side effects patients complain about most. A systematic review and meta-analysis found that anticholinergic side effects were roughly seven times more likely with amitriptyline than with placebo.⁴ The most frequently reported problems were dry mouth, drowsiness, sedation, and fatigue. That same analysis found that non-anticholinergic side effects were roughly as common on amitriptyline as on placebo, so the drug’s bad reputation really comes down to this one pharmacological property.

Interestingly, the review also found that anticholinergic side effects were not dose-dependent, which runs counter to what many clinicians assume.⁴ You might expect lower doses to produce fewer problems, and in practice the sedation does tend to be less overwhelming at lower doses, but the data across trials did not show a clean dose-response curve for these effects as a category. That finding matters because much of amitriptyline’s modern use involves low doses, as described below.

Overdose Risk and Cardiac Toxicity

The most serious concern with amitriptyline is what happens when someone takes too much. Tricyclic antidepressants as a class are dangerous in overdose, and amitriptyline appears to be one of the most toxic within the class. The primary mechanism is blockade of cardiac sodium channels, which disrupts the heart’s electrical conduction system. This can cause abnormal heart rhythms, dangerously low blood pressure, and cardiac arrest.⁵ In animal studies, intravenous amitriptyline produced conduction delays, irregular heart rhythms, and progressive drops in blood pressure within 30 minutes.⁶

This toxicity profile is the single biggest reason tricyclics lost their default status for depression treatment. When prescribing for a population that includes suicidal patients, the margin between a therapeutic dose and a potentially lethal dose matters enormously. SSRIs have a much wider margin of safety in overdose, and that practical advantage outweighed any edge amitriptyline might have in raw efficacy for the average outpatient with depression.

Where Amitriptyline Is Still Prescribed Today

Here is where the story gets interesting. While amitriptyline’s role in treating depression has shrunk, its use for other conditions has held steady or even grown. The drug’s multimodal mechanism, which includes effects on monoamine reuptake, various receptors, and ion channels, makes it useful for conditions involving pain signaling and nervous system sensitivity.⁷ Many of these uses involve doses well below the antidepressant range, which means fewer side effects and less risk.

Neuropathic Pain

Amitriptyline is recommended as a first-line treatment for neuropathic pain, the chronic burning or shooting pain that results from nerve damage, in many clinical guidelines worldwide.⁸ Conditions like diabetic neuropathy, postherpetic neuralgia (nerve pain after shingles), and other forms of nerve injury are common targets. The doses used are typically lower than what would be prescribed for depression. In a head-to-head trial comparing amitriptyline with nortriptyline (a related tricyclic with fewer side effects) for postherpetic neuralgia, the two drugs provided equivalent pain relief, but patients on amitriptyline reported more intolerable side effects.⁹ Some prescribers choose nortriptyline instead for that reason, but amitriptyline remains the most widely recognized name in this space.

Migraine Prevention

Amitriptyline has been used for migraine prevention since at least the late 1970s, when a controlled trial showed that about 55% of patients on the drug experienced at least a 50% reduction in migraine frequency, compared with 34% on placebo.¹⁰ A more recent European meta-analysis confirmed this benefit with moderate-certainty evidence, finding that amitriptyline roughly increased the chances of a meaningful reduction in monthly migraine days by about 60% compared to placebo.¹¹ This effect appears to be separate from the antidepressant action, meaning it works for migraine even in patients who are not depressed. Amitriptyline remains one of the most commonly prescribed preventive medications for migraine, though newer options like CGRP inhibitors have given patients with intolerable side effects an alternative.

Fibromyalgia

The evidence here is more complicated. A Cochrane review found no consistent differences between amitriptyline and placebo for symptoms like fatigue, poor sleep, and quality of life in fibromyalgia.¹² However, a later network meta-analysis comparing amitriptyline against FDA-approved fibromyalgia treatments told a different story, finding that amitriptyline was associated with meaningful improvements in sleep disturbances, fatigue, and quality of life compared with placebo.¹³ The disagreement between these analyses partly reflects differences in which studies each one included and how outcomes were measured. In practice, many rheumatologists and pain specialists still prescribe low-dose amitriptyline for fibromyalgia, especially when sleep disruption is a prominent symptom, since the sedating quality of the drug can become an advantage at bedtime.

Irritable Bowel Syndrome

Amitriptyline has gained traction as a second-line treatment for irritable bowel syndrome (IBS), particularly when first-line treatments have failed. Its anticholinergic properties, which are a nuisance in other contexts, may actually help here by reducing gut motility and visceral hypersensitivity.¹⁴ A large UK-based randomized trial found that low-dose amitriptyline, titrated by the patient at home, improved IBS symptoms in primary care. The researchers emphasized the importance of clear communication between doctor and patient to distinguish amitriptyline’s use for IBS from its historical identity as an antidepressant, since some patients resist taking it because of the association.¹⁵

The “Antidepressant” Label Problem

That last point deserves its own discussion because it comes up constantly. If you are prescribed amitriptyline for nerve pain, migraine, or IBS, you will see “antidepressant” on the pharmacy label and in the drug information sheet. This understandably confuses and sometimes alarms patients. Some worry their doctor secretly thinks they are depressed. Others are reluctant to fill the prescription because they associate antidepressants with stigma or with side effects they have heard about at full antidepressant doses.

The reality is that many drugs are used far outside their original indication. Amitriptyline at 10 to 25 milligrams for pain or IBS is a different clinical proposition than amitriptyline at 150 milligrams for depression. The side-effect burden is lighter, the overdose risk is lower, and the therapeutic goal is entirely different. Researchers who studied amitriptyline for IBS in primary care specifically recommended that doctors develop better ways of explaining this distinction to patients, because the label mismatch was a real barrier to treatment uptake.¹⁵ If your doctor prescribes amitriptyline and you do not have depression, it is worth asking what condition it is being used for and at what dose, rather than assuming the label tells the whole story.

Older Adults and Amitriptyline

One population where amitriptyline use has genuinely declined for good reason is older adults. The American Geriatrics Society’s Beers Criteria, which list medications considered potentially inappropriate for people over 65, include amitriptyline.¹⁶ The anticholinergic effects that bother younger patients can be genuinely dangerous in older ones: drowsiness increases fall risk, dry mouth contributes to dental problems, and there is growing concern about long-term anticholinergic burden and cognitive decline. Urinary retention and constipation, also anticholinergic effects, are more likely to become serious in older bodies.

This does not mean no elderly patient should ever take amitriptyline, but it does mean prescribers are expected to think twice and consider alternatives. Nortriptyline, for instance, has fewer anticholinergic effects and is sometimes substituted. Gabapentinoids or duloxetine may be used for pain. For migraine prevention in older adults, the calculus shifts toward drugs without the anticholinergic baggage. If you are over 65 and your doctor prescribes amitriptyline, it is reasonable to ask whether a less anticholinergic option would work for your situation.

Children and Adolescents

Amitriptyline is used in pediatric practice, mainly for headaches and functional abdominal pain, but the evidence base is weaker than many parents and prescribers assume. A narrative review of the pediatric literature noted that despite frequent use, the evidence supporting amitriptyline in children is not strong.¹⁷ The most striking example is the CHAMP trial, a rigorous multi-center study that compared amitriptyline, topiramate, and placebo for adolescent episodic migraine and found no evidence that amitriptyline outperformed placebo.¹⁷ For functional abdominal pain in children, amitriptyline showed some benefits for quality of life and anxiety but only reduced pain in one specific location.

The pediatric picture is a good reminder that evidence from adult trials does not automatically transfer to younger patients. The drug’s side effects, including sedation and cardiac rhythm effects, are also a concern in growing bodies, and pediatric overdose is particularly dangerous. Prescribing amitriptyline to a child or teenager is not unreasonable if other options have failed, but it should be a considered decision rather than a default one.

Drug Interactions Worth Knowing About

Because amitriptyline is metabolized by the cytochrome P450 enzyme system in the liver, it interacts with a long list of other medications that use the same pathways. Combining it with other drugs that raise serotonin levels, including certain other antidepressants, tramadol, and some migraine medications like triptans, can increase the risk of serotonin toxicity, a potentially dangerous condition involving agitation, rapid heart rate, and high body temperature.¹⁸ People also vary genetically in how efficiently they metabolize amitriptyline. Someone who is a slow metabolizer of the relevant enzyme may build up higher blood levels of the drug than expected at a standard dose, increasing side effects and toxicity risk.

If you are starting amitriptyline, make sure your prescriber knows about every other medication, supplement, and over-the-counter product you take. This is especially relevant because amitriptyline is often prescribed for conditions like chronic pain or IBS where patients may already be on multiple drugs.

Amitriptyline in Veterinary Medicine

One corner of amitriptyline use that surprises people is veterinary medicine. Tricyclic antidepressants are used in animals for behavioral disorders, including separation anxiety in dogs and anxiety-related urinary problems in cats.¹⁹ Amitriptyline has been specifically studied for recurrent idiopathic cystitis in cats, a frustrating condition with no clear cause. In one study, treatment successfully reduced clinical signs in about 60% of the cats treated.²⁰ The thinking is that amitriptyline’s combined effects on pain signaling, smooth muscle, and anxiety may address multiple facets of the condition simultaneously. If your veterinarian has ever prescribed amitriptyline for your pet, this is why, and it is the same drug your grandmother may have taken for her migraines.

1
ACS Chemical Neuroscience. Classics in Chemical Neuroscience: Amitriptyline
2
The Lancet. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
3
Depression and Anxiety. SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability
4
PLOS ONE. Amitriptyline’s anticholinergic adverse drug reactions–A systematic multiple-indication review and meta-analysis
5
PubMed. Tricyclic antidepressant poisoning: cardiovascular toxicity
6
PubMed. Experimental amitriptyline poisoning: treatment of severe cardiovascular toxicity with cardiopulmonary bypass
7
PubMed Central. A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia
8
PubMed Central. Amitriptyline for neuropathic pain in adults
9
PubMed. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial
10
JAMA Neurology. Amitriptyline in Migraine Prophylaxis
11
PubMed Central. European Headache Federation critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: amitriptyline
12
PubMed Central. Amitriptyline for fibromyalgia in adults
13
JAMA Network Open. Comparison of Amitriptyline and US Food and Drug Administration–Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis
14
PubMed Central. Efficacy of Amitriptyline in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis
15
PubMed Central. Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT
16
PubMed Central. Potentially Inappropriate Medications in a Psychogeriatric Inpatient Ward: An Audit Based on Beers Criteria
17
PubMed Central. Beyond Amitriptyline: A Pediatric and Adolescent Oriented Narrative Review of the Analgesic Properties of Psychotropic Medications for the Treatment of Complex Pain and Headache Disorders
18
PubMed Central. Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects
19
PubMed Central. The short-term clinical efficacy of amitriptyline in the management of idiopathic feline lower urinary tract disease: A controlled clinical study
20
PubMed. Amitriptyline treatment for severe recurrent idiopathic cystitis in cats